Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 26 Jan 2023 |
| 154,112 Orion Corporation A shares converted into B shares | 25 Jan 2023 |
| Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2023 Annual General Meeting | 12 Jan 2023 |
| 40,443 Orion Corporation A shares converted into B shares | 28 Dec 2022 |
| Orion Corporation: Acquisition of Own Shares 04.11.2022 | 4 Nov 2022 |